4//SEC Filing
AUBERTON-HERVE ANDRE-JACQUES 4
Accession 0001144204-18-019057
CIK 0001508381other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 7:26 PM ET
Size
10.8 KB
Accession
0001144204-18-019057
Insider Transaction Report
Form 4
AUBERTON-HERVE ANDRE-JACQUES
Director
Transactions
- Conversion
Common Stock
2018-03-31$0.06/sh+12,114,710$757,169→ 12,679,436 total(indirect: Shares held through Star SCI) - Award
Warrant
2017-08-14+1,600,640→ 1,600,640 total(indirect: Warrants held through held through Star SCI)Exercise: $0.06From: 2018-03-31Exp: 2022-08-14→ Common Stock (1,600,640 underlying) - Conversion
Common Stock
2018-03-31$0.06/sh+564,726$35,295→ 12,679,436 total(indirect: Shares held through 4A Consulting and Engineering)
Footnotes (3)
- [F1]On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
- [F2]On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
- [F3]As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.
Documents
Issuer
Bionik Laboratories Corp.
CIK 0001508381
Entity typeother
Related Parties
1- filerCIK 0001730329
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 7:26 PM ET
- Size
- 10.8 KB